Apyx Medical (APYX) Q3 2025 Earnings
How Did APYX Stock React to Q3 2025 Earnings?
S&P 500 over the same 30 days: +1.90%.
Did APYX Beat Earnings? Q3 2025 Results
Yes. Apyx Medical reported Q3 2025 earnings of $-0.05 a share on Nov 6, 2025, beating the $-0.10 consensus estimate by 51.2%. Revenue was $12.9M against a $12.0M estimate.
Apyx Medical delivered a notably strong third quarter, posting a loss of just $0.05 per share against a consensus estimate of $0.10, a 51.22% beat, while revenue climbed 12.1% year over year to $12.88 million, clearing the $12.00 million estimate by 7.30%. The primary engine behind the outperformance was the full commercial launch of its AYON Body Contouring System, which fueled a 19% surge in Surgical Aesthetics revenue and a domestic sales spike of over 30%, pushing gross margin to 64.4% from 60.5% a year earlier. Cost discipline added to the momentum, with operating expenses falling $1.50 million to $9.13 million, helping narrow the net loss sharply to $1.98 million from $4.70 million in the prior-year period. Analysts who follow <a href="https://247wallst.com/investing/2025/11/03/idexx-laboratories-jumps-15-on-q3-earnings-beat/">medical device earnings beats</a> this season have noted how margin expansion can accelerate loss reduction, and Apyx fits that pattern. The company raised its full-year 2025 revenue guidance to $50.50 million–$52.50 million, with Surgical Aesthetics guidance lifted to $43.00 million–$45.00 million as the AYON commercial ramp continues.
- AYON commercial launch drove Surgical Aesthetics revenue growth of 19% YoY
- Domestic Surgical Aesthetics sales increased over 30% from prior year period
- Increased volume of single-use handpieces in both domestic and international markets
- Favorable segment mix with Surgical Aesthetics comprising a higher percentage of total sales improved gross margin to 64.4%
- Operating expenses decreased $1.5 million year-over-year through broad-based cost reductions
“In September, we successfully transitioned the commercialization program for AYON from an effective soft launch targeting key regions to a full U.S. program. Initial feedback from leading board-certified plastic and cosmetic surgeons continues to be overwhelmingly positive, with several of them contributing at workshops and clinical symposia that drove strong engagement and resulted in pre-orders for AYON. While we are still in the early stages of ramping up the broader commercial program, I am excited to announce that we reported a 19% increase in Surgical Aesthetics revenue for the third quarter of 2025,”
Apyx Medical CEO, on the earnings call
What Was Apyx Medical's Outlook in Q3 2025?
Apyx Medical raised its full-year 2025 total revenue guidance to $50.5 million–$52.5 million, up from the prior range of $50.0 million–$52.0 million and well above the original guidance of $47.6 million–$49.5 million. Surgical Aesthetics revenue guidance was increased to $43.0 million–$45.0 million from the prior $42.0 million–$44.0 million. OEM revenue guidance was lowered to approximately $7.5 million from the prior $8.0 million. Total company operating expenses are expected to be less than $40.0 million for full-year 2025. The company anticipates further demand growth driven by pending FDA clearance for AYON label expansion to include power liposuction.
APYX YoY Financials
| Metric | Q3 2025 | Q3 2024 | Year over year |
|---|---|---|---|
| Revenue | $12.9M | $11.5M | +12.1% |
| Gross Profit | $8.3M | $7.0M | +19.3% |
| Operating Income | −$832,000 | −$469,765 | +77.1% |
| Net Income | −$2.0M | −$1.3M | +57.8% |
APYX Revenue by Segment
APYX Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.